Stockreport

Nuvation Bio outlines first-line IBTROZI growth strategy with 50-month median DOR amid expanding global partnerships [Seeking Alpha]

Nuvation Bio Inc. Class A  (NUVB) 
PDF David Hung, Founder, President, CEO & Chairman, highlighted that "2025 was a pivotal year for Nuvation Bio" due to the full U.S. FDA approval of IBTROZI for advanced RO [Read more]